Actinium-225 for targeted α therapy: Coordination chemistry and current chelation approaches

Nikki A. Thiele, Justin J. Wilson

Research output: Contribution to journalArticlepeer-review

121 Scopus citations

Abstract

The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT. This overview provides a starting point for researchers in the field of TAT to gain an understanding of this valuable therapeutic radionuclide.

Original languageEnglish
Pages (from-to)336-348
Number of pages13
JournalCancer Biotherapy and Radiopharmaceuticals
Volume33
Issue number8
DOIs
StatePublished - Oct 2018
Externally publishedYes

Funding

The authors acknowledge funding support from a Pilot Award from the Weill Cornell Medical College Clinical and Translational Science Center, funded by NIH/NCATS UL1TR00457.

FundersFunder number
NIH/NCATSUL1TR00457
Weill Cornell Medical College

    Keywords

    • actinides
    • actinium-225
    • coordination chemistry
    • macrocyclic ligands
    • radiopharmaceuticals
    • targeted α therapy

    Fingerprint

    Dive into the research topics of 'Actinium-225 for targeted α therapy: Coordination chemistry and current chelation approaches'. Together they form a unique fingerprint.

    Cite this